Edition:
United States

Acorda Therapeutics Inc (ACOR.OQ)

ACOR.OQ on NASDAQ Stock Exchange Global Select Market

28.20USD
17 Aug 2018
Change (% chg)

$0.35 (+1.26%)
Prev Close
$27.85
Open
$27.80
Day's High
$28.48
Day's Low
$27.45
Volume
79,285
Avg. Vol
144,192
52-wk High
$36.25
52-wk Low
$16.55

Chart for

About

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $1,339.04
Shares Outstanding(Mil.): 47.48
Dividend: --
Yield (%): --

Financials

  ACOR.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -3.16 -- --
ROI: -12.32 2.89 12.63
ROE: -22.38 1.65 14.82

UPDATE 2-Acorda loses bid for U.S. court order halting generic Ampyra sales

July 25 A U.S. appeals court on Wednesday denied a request by Acorda Therapeutics Inc for a temporary court order blocking generic drug companies from launching lower-cost versions of its multiple sclerosis drug Ampyra.

Jul 25 2018

Acorda loses bid for U.S. court order halting generic Ampyra sales

A U.S. appeals court on Wednesday denied a request by Acorda Therapeutics Inc for a temporary court order blocking generic drug companies from launching lower-cost versions of its multiple sclerosis drug Ampyra.

Jul 25 2018

Drugmakers oppose Acorda's bid to block generic MS drug's release

Three generic drug manufacturers are urging a federal appeals court to reject Acorda Therapeutics Inc's "extraordinary" request for an order blocking them from launching a generic version of multiple sclerosis drug Ampyra before the case is decided.

May 31 2018

BRIEF-Hls Therapeutics Announces Qtrly Net Loss $0.19 Per Common Share

* QTRLY NET LOSS $0.19 PER COMMON SHARE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

May 16 2018

BRIEF-vTv Therapeutics Q1 GAAP Loss Per Share $0.30

* VTV THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL AND OPERATIONAL RESULTS AND RECENT HIGHLIGHTS

May 15 2018

BRIEF-Acer Therapeutics Q1 Loss Per Share $0.53

* ACER THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 14 2018

BRIEF-Abeona Therapeutics Posts Q1 Loss Of $0.18 Per Share

* ABEONA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

May 11 2018

BRIEF-Acorda Therapeutics Reports Q1 Non-GAAP Earnings Per Share Of $0.14

* ACORDA PROVIDES FINANCIAL AND PIPELINE UPDATE FOR FIRST QUARTER 2018

May 02 2018

BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer

* AXSOME THERAPEUTICS APPOINTS NICK PIZZIE, CPA, MBA, AS CHIEF FINANCIAL OFFICER

Apr 19 2018

BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer

* ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER

Apr 02 2018

Earnings vs. Estimates